NRX Pharmaceuticals Files 8-K
Ticker: NRXPW · Form: 8-K · Filed: May 16, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | May 16, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $7.5 million, $22.5 million, $30 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, company-update
TL;DR
NRX Pharma dropped an 8-K on 5/16 detailing operations & financials as of 5/14.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on May 16, 2024, reporting on events as of May 14, 2024. The filing includes information on results of operations, financial condition, Regulation FD disclosures, and other events, along with financial statements and exhibits. The company was formerly known as Big Rock Partners Acquisition Corp. and changed its name on October 12, 2017.
Why It Matters
This 8-K filing provides crucial updates on NRX Pharmaceuticals' operational and financial status, offering insights into recent developments and regulatory disclosures.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on operational and financial information, not indicating immediate significant risk.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former Company Name
- May 14, 2024 (date) — Date of earliest event reported
- May 16, 2024 (date) — Date of Report
- October 12, 2017 (date) — Date of Name Change
FAQ
What specific items are covered in the 8-K filing by NRX Pharmaceuticals?
The 8-K filing covers Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 14, 2024.
What was NRX Pharmaceuticals, Inc. formerly known as?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp.
On what date did the company change its name from Big Rock Partners Acquisition Corp.?
The company changed its name on October 12, 2017.
What is the Standard Industrial Classification code for NRX Pharmaceuticals, Inc.?
The Standard Industrial Classification code for NRX Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 9.7 · Accepted 2024-05-15 20:16:50
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
- $7.5 million — -binding term sheet providing for up to $7.5 million in debt capital to replace certain toxi
- $22.5 million — rovides for additional capital of up to $22.5 million. The Press Release referred to addition
- $30 m — o additional available capital of up to $30 million, which included the initial $7.5
Filing Documents
- nrxp-20240514x8k.htm (8-K) — 45KB
- nrxp-20240514xex99d1.htm (EX-99.1) — 50KB
- nrxp-20240514xex99d1001.jpg (GRAPHIC) — 2KB
- nrxp-20240514xex99d1004.jpg (GRAPHIC) — 156KB
- 0001558370-24-008337.txt ( ) — 483KB
- nrxp-20240514.xsd (EX-101.SCH) — 4KB
- nrxp-20240514_def.xml (EX-101.DEF) — 14KB
- nrxp-20240514_lab.xml (EX-101.LAB) — 20KB
- nrxp-20240514_pre.xml (EX-101.PRE) — 15KB
- nrxp-20240514x8k_htm.xml (XML) — 7KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On May 14, 2024, NRx Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the first quarter ending March 31, 2024 (the " Press Release ). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure See Item 2.02.
01 Other Events
Item 8.01 Other Events The Press Release includes disclosure regarding the Company's execution of a non-binding term sheet providing for up to $7.5 million in debt capital to replace certain toxic debt (" Term Sheet "). The Term Sheet also provides for additional capital of up to $22.5 million. The Press Release referred to additional available capital of up to $30 million, which included the initial $7.5 million. Availability of capital under the Term Sheet is conditioned upon the completion of due diligence and the execution of definitive agreements.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by NRx Pharmaceuticals, Inc., dated May 14, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) The information contained in Items 2.02 and 7.01 of this Current Report on Form 8-K, and Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: May 15, 2024 By: /s/ Stephen Willard Name: Stephen Willard Title: Chief Executive Officer